DI B4

Drug Profile

DI B4

Alternative Names: Anti-CD19 monoclonal antibody - Merck KGaA; DI-B4

Latest Information Update: 17 Jan 2014

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer Cancer Research Technology; Cancer Research UK
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia

Most Recent Events

  • 24 Jul 2013 Phase-I clinical trials in B-cell lymphoma and Chronic lymphocytic leukaemia (late-stage disease, second-line therapy or greater) in United Kingdom (IV)
  • 04 Jan 2010 Preclinical trials in B-cell lymphoma in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top